Live feed06:30:00·1463dPRReleasevia QuantisnowSage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary EndpointsByQuantisnow·Wall Street's wire, on your screen.BIIB· Biogen Inc.SAGE· Sage Therapeutics Inc.Health Care
